ArticleInternational journal of nephrology2010
The cardiorenal syndrome: a review.
Article in International journal of nephrology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- 48-year-old with Altered Mental Status and Respiratory Failure: A Case Report.Clinical practice and cases in emergency medicine · 2021Article
- Article
- miR-21, Mediator, and Potential Therapeutic Target in the Cardiorenal Syndrome.Frontiers in pharmacology · 2020Review
- Pathological cardiac remodeling occurs early in CKD mice from unilateral urinary obstruction, and is attenuated by Enalapril.Scientific reports · 2018Article
- Oxidative Stress and Cardiovascular Complications in Chronic Kidney Disease, the Impact of Anaemia.Pharmaceuticals (Basel, Switzerland) · 2018Review
- N-Acetylcysteine Attenuates the Development of Renal Fibrosis in Transgenic Mice with Dilated Cardiomyopathy.Scientific reports · 2017Article
- Local and systemic renin-angiotensin system participates in cardiopulmonary-renal interactions in monocrotaline-induced pulmonary hypertension in the rat.Molecular and cellular biochemistry · 2016Article
- Lipocalin 2 (LCN2) Expression in Hepatic Malfunction and Therapy.Frontiers in physiology · 2016Review
- Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin.Clinical research in cardiology : official journal of the German Cardiac Society · 2015Review
- A review of acute and chronic peritoneal dialysis in developing countries.Clinical kidney journal · 2015Article
- Diastolic dysfunction and contrast-induced nephropathy in patients undergoing coronary angiography.Herz · 2015Observational
- Elevation of urinary liver-type fatty acid binding protein after cardiac catheterization related to cardiovascular events.International journal of nephrology and renovascular disease · 2015Article
- Advances in the pathogenesis of cardiorenal syndrome type 3.Oxidative medicine and cellular longevity · 2015Review
- Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis.Journal of the American Heart Association · 2014Article
- Olmesartan medoxomil reverses glomerulosclerosis in renal tissue induced by myocardial infarction without changes in renal function.Experimental and therapeutic medicine · 2014Article
- Obesity-related cardiorenal disease: the benefits of bariatric surgery.Nature reviews. Nephrology · 2013Review
- Worsening renal function is not associated with response to treatment in acute heart failure.International journal of cardiology · 2013Article
- Cardiorenal syndrome: Resistant to diuretics, sensitive to ultraflitration.Journal of cardiovascular disease research · 2012Article
- Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?The open cardiovascular medicine journal · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiorenal syndrome (CRS) is the umbrella term used to describe clinical conditions in which cardiac and renal dysfunctions coexist. Much has been written on this subject, but underlying pathophysiological mechanisms continue to be unravelled and implications for management continue to be debated. A classification system-incorporating five subtypes-has recently been proposed though it has yet to permeate into day-to-day clinical practice. CRS has garnered much attention from both the cardiological and nephrological communities since the condition is associated with significant morbidity and mortality. Renal dysfunction is highly prevalent amongst patients with heart failure and has been shown to be as powerful and independent a marker of adverse prognosis as ejection fraction. Similarly, patients with renal failure are considerably more likely to suffer cardiovascular disease than matched subjects from the general population. This paper begins by reviewing the epidemiology and classification of CRS before going on to consider the different pathological mechanisms underlying cardiorenal dysfunction. We then focus on management strategies and conclude by discussing future directions in the diagnosis and management of patients suffering with CRS.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.